These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 32969362)

  • 1. Efficacy of Seven-day High-dose Esomeprazole-based Triple Therapy versus Seven-day Standard Dose Non-esomeprazole-based Triple Therapy as the First-line Treatment of Patients with
    Lee YD; Kim SE; Park SJ; Park MI; Moon W; Kim JH; Jung K; Song J
    Korean J Gastroenterol; 2020 Sep; 76(3):142-149. PubMed ID: 32969362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of first-line triple therapy with levofloxacin and amoxicillin plus esomeprazole or rabeprazole for the eradication of Helicobacter pylori infection and the effect of CYP2C19 genotype: a 1-week, randomized, open-label study in Chinese adults.
    Pan X; Li Y; Qiu Y; Tang Q; Qian B; Yao L; Shi R; Zhang G
    Clin Ther; 2010 Nov; 32(12):2003-11. PubMed ID: 21118735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-line eradication for Helicobacter pylori-positive gastritis by esomeprazole-based triple therapy is influenced by CYP2C19 genotype.
    Saito Y; Serizawa H; Kato Y; Nakano M; Nakamura M; Saito H; Suzuki H; Kanai T
    World J Gastroenterol; 2015 Dec; 21(48):13548-54. PubMed ID: 26730167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 14 day esomeprazole- and amoxicillin-containing high-dose dual therapy regimen achieves a high eradication rate as first-line anti-Helicobacter pylori treatment in Taiwan: a prospective randomized trial.
    Tai WC; Liang CM; Kuo CM; Huang PY; Wu CK; Yang SC; Kuo YH; Lin MT; Lee CH; Hsu CN; Wu KL; Hu TH; Chuah SK
    J Antimicrob Chemother; 2019 Jun; 74(6):1718-1724. PubMed ID: 30768161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trends in Helicobacter pylori eradication rates by first-line triple therapy and related factors in eradication therapy.
    Kim SE; Park MI; Park SJ; Moon W; Choi YJ; Cheon JH; Kwon HJ; Ku KH; Yoo CH; Kim JH; Lee GW; Song SE
    Korean J Intern Med; 2015 Nov; 30(6):801-7. PubMed ID: 26552455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Effect of Proton-Pump Inhibitors on the Success of Triple and Quadruple Therapy for Helicobacter pylori Infection.
    Boltin D; Levi Z; Gingold-Belfer R; Schmilovitz-Weiss H; Shochat T; Dickman R; Perets TT; Dotan I; Niv Y
    Dig Dis; 2020; 38(5):408-414. PubMed ID: 31910424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the efficacy of 1-day high-dose quadruple therapy versus 7-day triple therapy for treatment of Helicobacter pylori infection.
    Zheng Q; Pan Y; Zhang L; Xiao SD
    Chin J Dig Dis; 2005; 6(4):202-5. PubMed ID: 16246231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized Clinical Trial: Esomeprazole, Bismuth, Levofloxacin, and Amoxicillin or Cefuroxime as First-Line Eradication Regimens for Helicobacter pylori Infection.
    Fu W; Song Z; Zhou L; Xue Y; Ding Y; Suo B; Tian X; Wang L
    Dig Dis Sci; 2017 Jun; 62(6):1580-1589. PubMed ID: 28391418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fourteen-day high-dose esomeprazole, amoxicillin and metronidazole as third-line treatment for Helicobacter pylori infection.
    Puig I; González-Santiago JM; Molina-Infante J; Barrio J; Herranz MT; Algaba A; Castro M; Gisbert JP; Calvet X
    Int J Clin Pract; 2017 Sep; 71(9):. PubMed ID: 28869699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative study of the effect of 10-day esomeprazole containing levofloxacin versus clarithromycin sequential regimens on the treatment of Iranian patients with
    Mokhtare M; Nikkhah M; Behnam B; Agah S; Bahardoust M; Masoodi M; Faghihi A
    Indian J Pharmacol; 2020; 52(4):266-271. PubMed ID: 33078727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two-week, high-dose proton pump inhibitor, moxifloxacin triple Helicobacter pylori therapy after failure of standard triple or non-bismuth quadruple treatments.
    Gisbert JP; Romano M; Molina-Infante J; Lucendo AJ; Medina E; Modolell I; Rodríguez-Tellez M; Gomez B; Barrio J; Perona M; Ortuño J; Ariño I; Domínguez-Muñoz JE; Perez-Aisa Á; Bermejo F; Domínguez JL; Almela P; Gomez-Camarero J; Millastre J; Martin-Noguerol E; Gravina AG; Martorano M; Miranda A; Federico A; Fernandez-Bermejo M; Angueira T; Ferrer-Barcelo L; Fernández N; Marín AC; McNicholl AG
    Dig Liver Dis; 2015 Feb; 47(2):108-13. PubMed ID: 25454706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication.
    Nista EC; Candelli M; Zocco MA; Cremonini F; Ojetti V; Finizio R; Spada C; Cammarota G; Gasbarrini G; Gasbarrini A
    Am J Gastroenterol; 2006 Sep; 101(9):1985-90. PubMed ID: 16968503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [10-day triple therapy with esomeprazole 40 mg/12 h vs. quadruple concomitant non-bismuth therapy as first line treatment for Helicobacter pylori infection].
    Campillo A; Amorena E; Ostiz M; Kutz M; LaIglesia M
    Gastroenterol Hepatol; 2016 Nov; 39(9):584-589. PubMed ID: 27084668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Study of Clarithromycin- versus Metronidazole-Based Triple Therapy as First-Line Eradication for Helicobacter pylori.
    Adachi T; Matsui S; Watanabe T; Okamoto K; Okamoto A; Kono M; Yamada M; Nagai T; Komeda Y; Minaga K; Kamata K; Yamao K; Takenaka M; Asakuma Y; Sakurai T; Nishida N; Kashida H; Kudo M
    Oncology; 2017; 93 Suppl 1():15-19. PubMed ID: 29258111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective trial in Saudi Arabia comparing the 14-day standard triple therapy with the 10-day sequential therapy for treatment of Helicobacter pylori infection.
    Alsohaibani F; Al Ashgar H; Al Kahtani K; Kagevi I; Peedikayil M; Alfadda A; Khan M
    Saudi J Gastroenterol; 2015; 21(4):220-5. PubMed ID: 26228365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequential therapy for first-line Helicobacter pylori eradication: 10- or 14-day regimen?
    Zullo A; Fiorini G; Scaccianoce G; Portincasa P; De Francesco V; Vassallo R; Urban F; Monica F; Mogavero G; Amato A; Vaira D
    J Gastrointestin Liver Dis; 2019 Mar; 28(1):11-14. PubMed ID: 30851166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two-week Triple Therapy with either Standard or High-dose Esomeprazole for First-line H. pylori Eradication.
    De Francesco V; Ridola L; Hassan C; Bellesia A; Alvaro D; Vaira D; Zullo A
    J Gastrointestin Liver Dis; 2016 Jun; 25(2):147-50. PubMed ID: 27308644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy of second-line anti-Helicobacter pylori therapy using an extended 14-day levofloxacin/amoxicillin/proton-pump inhibitor treatment--a pilot study.
    Chuah SK; Tai WC; Hsu PI; Wu DC; Wu KL; Kuo CM; Chiu YC; Hu ML; Chou YP; Kuo YH; Liang CM; Chiu KW; Hu TH
    Helicobacter; 2012 Oct; 17(5):374-81. PubMed ID: 22967121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimum duration of regimens for Helicobacter pylori eradication.
    Yuan Y; Ford AC; Khan KJ; Gisbert JP; Forman D; Leontiadis GI; Tse F; Calvet X; Fallone C; Fischbach L; Oderda G; Bazzoli F; Moayyedi P
    Cochrane Database Syst Rev; 2013 Dec; (12):CD008337. PubMed ID: 24338763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fourteen- vs seven-day bismuth-based quadruple therapy for second-line Helicobacter pylori eradication.
    Hwang JJ; Lee DH; Lee AR; Yoon H; Shin CM; Park YS; Kim N
    World J Gastroenterol; 2015 Jul; 21(26):8132-9. PubMed ID: 26185386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.